Solid Biosciences Inc.

SLDB Nasdaq SEC CIK 1707502
Follow Solid Biosciences Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Net income −$53.9M −17.9% vs same quarter last year
EPS, diluted −$0.36 +25% vs same quarter last year
Operating cash flow −$45.5M −36.1% vs same quarter last year
Operating income −$57.7M −20% vs same quarter last year
Net income by quarter
−$42.6M
−$39.3M
−$39.5M
−$45.8M
−$49.8M
−$56.7M
−$54.8M
−$53.9M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income10 fiscal years
  • Revenue
  • Net income
−$200M−$150M−$100M−$50M$0$50MFY17FY19FY21FY23FY25
Show the numbers
YearRevenueNet income
FY25-−$174.3M
FY24-−$124.7M
FY23-−$96M
FY22$8.1M−$86M
FY21$13.6M−$72.2M
FY20$0−$88.3M
FY19$0−$117.2M
FY18$0−$74.8M
FY17$0−$52.1M
FY16$0−$21.5M
Free cash flowOperating cash flow minus capital expenditure
−$200M−$150M−$100M−$50M$0FY17FY19FY21FY23FY25
Show the numbers
YearFree cash flow
FY25−$157.4M
FY24−$100.7M
FY23−$95.7M
FY22−$101M
FY21−$79M
FY20−$57.5M
FY19−$97.1M
FY18−$78M
FY17−$45.5M
FY16−$20.5M